Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$20.88 - $35.19 $10,440 - $17,595
-500 Reduced 24.7%
1,524 $45,000
Q1 2022

May 13, 2022

SELL
$29.0 - $47.27 $203,000 - $330,890
-7,000 Reduced 77.57%
2,024 $65,000
Q4 2021

Feb 14, 2022

BUY
$42.59 - $55.02 $277,857 - $358,950
6,524 Added 260.96%
9,024 $402,000
Q3 2021

Nov 15, 2021

SELL
$48.48 - $78.23 $172,249 - $277,951
-3,553 Reduced 58.7%
2,500 $126,000
Q2 2021

Aug 13, 2021

BUY
$50.3 - $78.44 $251,500 - $392,200
5,000 Added 474.83%
6,053 $475,000
Q1 2021

May 13, 2021

SELL
$53.8 - $81.53 $914 - $1,386
-17 Reduced 1.59%
1,053 $60,000
Q4 2020

Feb 16, 2021

BUY
$36.89 - $93.56 $39,472 - $100,109
1,070 New
1,070 $90,000
Q1 2020

May 15, 2020

SELL
$14.2 - $27.98 $32,887 - $64,801
-2,316 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$13.88 - $21.75 $32,146 - $50,373
2,316 New
2,316 $48,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.73B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.